Background: After introduction of up-titration strategy, there are limited data on comparison between the effects of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blocker (ARB) in patients with heart failure with reduced ejection fraction (HFrEF). The study sought to investigate the association between treatment with ARB at discharge and clinical outcomes in patients with HFrEF compared with treatment with ACEI or no renin angiotensin system blocker (RASB). Methods: The KorAHF registry is a prospective multicenter cohort and included patients who were hospitalized for acute heart failure (AHF). We studied 3005 patients with HFrEF (< 40%), and divided into ARB (n = 1190), ACEI (n = 1090), and no RASB (n = 725) groups. Propensity score matching was performed. Results: All-cause death occurred in 346 patients (29.1%) in the ARB group, 315 patients (28.9%) in the ACEI group, and 305 (42.1%) in the no RASB group. After propensity score matching (ARB vs. ACEI, 827 pairs), there was no significant difference between the two groups in the rate of death (HR 0.91, 95% CI 0.76–1.09, p = 0.32). All-cause death was significantly lower in the ARB group than in the no RASB group (ARB vs. no RASB, 538 pairs, HR 0.69, 95% CI 0.56–0.83, p < 0.001). The ARB group had a significantly lower discontinuation rate than the ACEI group (20.8% vs. 33.6%, p < 0.001). Conclusions: For treatment of AHF with reduced EF after hospitalization, ARB at discharge shows a mortality benefit comparable to that of ACEI. In addition, tolerability of medication was greater for ARB than for ACEI.
Bibliographical noteFunding Information:
This work was supported by Research of Korea Centers for Disease Control and Prevention [ 2010-E63003-00 , 2011-E63002-00 , 2012-E63005-00 , 2013-E63003-00 , 2013-E63003-01 , 2013-E63003-02 , and 2016-ER6303-00 ].
© 2017 Elsevier B.V.
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine